Cannabis Science Signs Exclusive Joint Venture Deal with
German-based Dupetit Natural Products, GmbH to Immediately Expand New
and Existing Product Lines Across Europe and Internationally
July 31, 2012
COLORADO SPRINGS, Colo.-- Cannabis Science (CBIS), a pioneering U.S.
Biotech Company developing pharmaceutical products for global public
health challenges is excited to announce the finalization of a deal with
German botanical product company, Dupetit Natural Products, GmbH.
Cannabis Science and Dupetit Natural Products have teamed together to
develop new products using our combined cannabinoid expertise. The Joint
Venture will immediately release the Cannabis Science current product
line, Dupetit Natural products, and new Jointly developed product lines
in the USA, Europe, and Internationally.
The Joint Venture Agreement signed with Dupetit is designed to
release products immediately in the developing European market and the
United States thereby expanding our international presence. The deal
will bring new products, revenues, and executive management to Cannabis
Science’s expanding operations. Dupetit has established itself in the
European markets and around the world, while meeting Cannabis Science’s
standards to ensure the utmost in quality control and stringent
procedures. Cannabis Science has great confidence the new jointly
developed products and the current Dupetit product line will be embraced
nation wide and internationally.
The JV will focus on the critical health aspect of the industry in
Europe and the USA. The products types that are immediately available
for distribution by the JV are capsules, creams, extract, essential
oils, targeting critical ailments such as cancer, aids, pain management,
PTSD, skin issues, and other critical ailments listed on the Cannabis
Science website, www.cannabisscience.com.
The Nutraceutical over the counter market will get an instant
boost as Dupetit and Cannabis Science both have products ready to go
such as the previously announced product line of lip balms, skin creams,
sun block will be enhanced by the European line of natural scented
cosmetics, organic hemp oil.
Cannabis Science’s goals to produce over the counter skin products
and other consumer products are a perfect match for Dupetit and their
years of experience developing over the counter hemp products. The JV
will produce a variety of natural food products and many more naturally
sweetened products including CannaBiscuits, lollipops, colas, lemonades,
chocolates, chewing gum, mints, and many more items. Additionally, the
JV will target clothing lines, perfumes, fertilizers and seed genetics,
as well other exciting new developments to be announced.
The JV mapping out a marketing plan to showcase their newly acquired
products and educate the general public on the effective use of
cannabinoids in the human body. Dupetit’s founder, Alberto
Dupetit-Bernardi, will manage the JV as the Vice President of European
Operations. The JV will be headquarter at his European location in
Germany. Cannabis Science is very excited to add Dupetit’s fantastic
team to its roster of professionals. If you would like to view the
existing products of Dupetit Natural Products, you may visit their
website http://www.dupetit.de/ for more information.
About Cannabis Science, Inc.
Cannabis Science, Inc. is conducting cannabinoid research and development for unmet medical needs. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize Phytocannabinoid-based pharmaceutical products.
Cannabis Science, Inc. is conducting cannabinoid research and development for unmet medical needs. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize Phytocannabinoid-based pharmaceutical products.
Cannabis Science is currently working with CBR International to
develop a Pre-IND Application to the FDA that focuses on the use of
CS-S/BCC-1 topical cannabis-based preparations for the treatment of
basal and squamous cell carcinomas.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Contact:
Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO
1-888-889-0888
info@cannabisscience.com
www.cannabisscience.com
or
Robert Kane
VP of Investor Relations
1-561-234-6929
rkane@cannabisscience.com
info@cannabisscience.com
source: www.cannabisscience.com
Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO
1-888-889-0888
info@cannabisscience.com
www.cannabisscience.com
or
Robert Kane
VP of Investor Relations
1-561-234-6929
rkane@cannabisscience.com
info@cannabisscience.com
source: www.cannabisscience.com
Posts
No comments:
Post a Comment